Panmure Liberum acted as Nominated Adviser, Joint Bookrunner and Joint Broker on Scancell Holdings plc’s upsized £11.3 million fundraise
We are pleased to announce that Panmure Liberum has acted as Nominated Adviser, Joint Bookrunner and Joint Broker on a significantly oversubscribed fundraise for Scancell, raising gross proceeds of £11.3 million through a placing, subscription and retail offer.
Scancell is a clinical stage immunotherapy company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer.
The net use of proceeds of the fundraise is expected to allow the company to further progress its lead cancer vaccine SCIB1 and the next generation iSCIB1+ to treat advanced melanoma, whilst also extending the group's cash runway to the second half of 2026.
Panmure Liberum Team:
Investment Banking – Emma Earl, Will Goode, Mark Rogers, Josh Moss
Corporate Broking – Rupert Dearden, Rauf Munir, Sam Elder
ECM – Graham Smith
Research – Julie Simmonds
Sales – David Cox
CIR – Sarah Downing
